Technology
Health
Biotechnology
ProQR Therapeutics
$12.579876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.
$12.57
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
-$0.06 (-0.49%) Today
+$0.30 (2.44%) After Hours
Why Robinhood?
You can buy or sell PRQR and other stocks, options, ETFs, and crypto commission-free!
About
ProQR Therapeutics NV operates as a biopharmaceutical company, which engages in the discovery and development of Ribonucleic Acid RNA based therapeutics for the treatment of genetic disorders. Its initial focus is on the development of a disease-modifying therapy for the treatment of cystic fibrosis. Read More The company was founded by Daniel de Boer, Gerard Platenburg, Henri Termeer and Dinko Valerio on February 21, 2012 and is headquartered in Leiden, the Netherlands.
Employees
—
Headquarters
Leiden, Zuid-Holland
Founded
2012
Market Cap
529.45M
Price-Earnings Ratio
—
Dividend Yield
0.00
Average Volume
290.75K
High Today
$12.66
Low Today
$11.88
Open Price
$12.35
Volume
137.48K
52 Week High
$24.00
52 Week Low
$5.10
Collections
Technology
Health
Biotechnology
Therapy
Biopharmaceutical
Pharmaceutical
2014 IPO
Europe (Non-UK)
News
Price Paid on Robinhood
15% Lower
Right Now
52 Week Low
$5.10
Average Price Paid
$14.76
52 Week High
$24.00
Earnings
-$0.49
-$0.35
-$0.22
-$0.08
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Estimated
—
Actual
Expected Aug 7, Pre-Market